Best Daily Inhaler for Type 1 Diabetes with Mild Asthma
For a patient with type 1 diabetes and mild asthma, start with a low-dose inhaled corticosteroid (ICS) taken daily, with as-needed short-acting beta-agonist (SABA) for quick relief. 1
Primary Recommendation: Low-Dose Inhaled Corticosteroid
Patients requiring short-acting beta-agonists more than 2-3 times per day should be treated with inhaled steroids. 2 For mild persistent asthma (step 2 therapy), low-dose ICS is the preferred daily controller medication. 1
Specific ICS Options and Dosing
- Budesonide, beclomethasone, or fluticasone are all appropriate choices, as there is no good evidence of clinically important differences between different inhaled steroids. 2
- Choose the least expensive ICS that the patient can use correctly and that controls symptoms. 2
- ICS should be administered twice daily for optimal efficacy in most patients. 2
- Once-daily dosing may be considered for patients with adherence concerns, as studies show once-daily budesonide can be as effective as twice-daily administration in mild to moderate asthma. 3, 4
Diabetes-Specific Considerations
Low to moderate doses of inhaled corticosteroids (up to 825 mcg budesonide equivalent daily) do not significantly affect fasting glucose levels in patients with diabetes. 5 This is critical reassurance for T1DM patients who may be concerned about steroid effects on glycemic control.
- Inhaled steroids in standard doses for mild asthma pose minimal risk to diabetes control. 5
- The effect of asthma on diabetes is not significant except in severe asthma cases. 5
Alternative Option for Step 2 Therapy
For patients aged 12 and older with mild persistent asthma, concomitant ICS and SABA used together as-needed is a conditionally recommended alternative to daily ICS, though this requires separate inhalers in the United States. 6, 7 This approach:
- Results in noninferior asthma control regarding exacerbations compared to routine daily ICS. 6
- Reduces total ICS exposure. 6
- May be inferior for symptom control compared to daily ICS. 6
- Requires more patient instruction than simple daily ICS use. 6
When to Add Long-Acting Beta-Agonist
If symptoms are not controlled on low-dose ICS alone, add a long-acting beta-agonist (LABA) rather than increasing ICS dose. 1, 8
- The combination of low-dose ICS plus LABA is preferred over medium-dose ICS alone for step 3 therapy. 1
- LABAs should never be used as monotherapy—they must always be combined with ICS. 1, 8
- Formoterol or salmeterol are appropriate LABA options. 8
Leukotriene Receptor Antagonists as Alternative
Montelukast is an appropriate alternative for mild persistent asthma if the patient is unable or unwilling to use ICS. 1 However:
- ICS remains the preferred option. 1
- Montelukast offers ease of use (once daily oral medication) and high compliance rates. 1
- It is less effective than ICS for most outcomes but may be suitable for specific patients. 1
Critical Implementation Points
Inhaler Technique
Ensure the patient can use their inhaler device correctly before prescribing. 2 Poor inhaler technique is a major cause of treatment failure. 9, 10
- Check and record inhaler technique. 11
- Consider using a spacer device with metered-dose inhalers to increase lung deposition. 2
- If technique is inadequate, consider switching to a dry powder inhaler, which many patients find easier to use. 10, 12
Monitoring and Follow-Up
- Patients should have a peak flow meter and written self-management plan. 11
- Increasing use of SABA to more than 2 days per week indicates inadequate control and need to step up therapy. 1
- Reassess after 3 months of stability before considering step-down. 2
Common Pitfall to Avoid
Do not prescribe LABA without concurrent ICS, as this increases risk of severe exacerbations and asthma-related deaths. 1 Always use combination therapy if LABA is indicated.